56 search results for: type 2 inflammation

Immune System, Microbiome and Neuroimmune Crosstalk in the Skin: Implications for AD
expert video

Immune System, Microbiome and Neuroimmune Crosstalk in the Skin: Implications for AD

Dermatology
The role of dysbiosis in the propagation of type 2 inflammation and itch in atopic dermatitis – a presentation from the ADVENT symposium at ISID 2023.
View more
ADVENT On Air | Charting a New Course: The Frontier of Early Intervention and Disease Modification in AD
Podcast

ADVENT On Air | Charting a New Course: The Frontier of Early Intervention and Disease Modification in AD

Dermatology
Join Drs. April Armstrong and Lisa Beck for a conversation around the long-term burden and effects of AD. They will discuss the underlying pathophysiology of AD and how early intervention and disease modification may impact disease course.
View more
Neuroimmune Axis in Atopic Dermatitis
expert video

Neuroimmune Axis in Atopic Dermatitis

Dermatology
A review of the neuroimmune mechanisms and changes to skin barrier that result in itch in AD.
View more
What role does IL-4 and IL-13 have in driving <b>Type</b> <b>2</b> inflammatory skin disease (AD, PN, CSU)?
expert video

What role does IL-4 and IL-13 have in driving Type 2 inflammatory skin disease (AD, PN, CSU)?

Dermatology
Dr. Oscar Palomares explains that IL-4 and IL-13 are crucial cytokines in type 2 inflammation, playing both unique and overlapping roles, including T cell expansion and contributing to clinical symptoms in chronic diseases.
View more
ADVENT On Air | The Road Ahead: Achieving Remission for ​Patients With Asthma
Podcast

ADVENT On Air | The Road Ahead: Achieving Remission for ​Patients With Asthma

Pulmonology
Join Professors Klaus Rabe and Ian Pavord as they discuss the importance of on-treatment clinical remission as a goal in asthma management.
View more
The Disease Burden of AD in Children and the Impact of <b>Type</b> <b>2</b> Comorbidities 
expert video

The Disease Burden of AD in Children and the Impact of Type 2 Comorbidities 

Dermatology
Multidimensional disease burden of atopic dermatitis in children from a real-world case study – Presentation from the ADVENT symposium at EAACI 2023.
View more
Skin Barrier Dysfunction and Increased Risk of Allergen Sensitization May Impact Atopic March in Atopic Dermatitis (AD)
Infographic

Skin Barrier Dysfunction and Increased Risk of Allergen Sensitization May Impact Atopic March in Atopic Dermatitis (AD)

Dermatology
An infographic exploring the process of allergen sensitization and the impact it may have on the development of atopic comorbidities in children with AD.
View more
Current systemic therapies have been shown to induce remission in a subset of AD patients
expert video

Current systemic therapies have been shown to induce remission in a subset of AD patients

Dermatology
Dr. Ramien discusses evidence suggesting early targeted inhibition in pediatric patients may prevent disease progression or lead to remission.
View more
Can targeting IL-4 and IL-13 have an effect on relieving the burden of atopic and non-atopic comorbidities in AD?
expert video

Can targeting IL-4 and IL-13 have an effect on relieving the burden of atopic and non-atopic comorbidities in AD?

Dermatology
Dr. Amy Paller discusses how targeting IL-4 and IL-13 can improve burden of AD.
View more
ADVENT On Air | Exploring The Urgency to Treat in Atopic Dermatitis
Podcast

ADVENT On Air | Exploring The Urgency to Treat in Atopic Dermatitis

Dermatology
Professor Lisa Beck explores the chronic and persistent burden of atopic dermatitis (AD) as well as the concept of early intervention in patients with AD.
View more
On-Treatment Clinical Remission in Asthma Patients Case Tool
interactivity

On-Treatment Clinical Remission in Asthma Patients Case Tool

Pulmonology
Review a severe asthma patient case to learn more about assessing asthma control and on-treatment clinical remission.
View more
Impact of Advanced Systemic Therapies on Disease Control in AD
expert video

Impact of Advanced Systemic Therapies on Disease Control in AD

Dermatology
Dr. Simpson discusses impact of advanced systemic therapies in AD, and the link between inhibition of type 2 inflammation and reduced IgE levels.
View more

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: IndiaChange country/region